For each clinical trial application related to the use of genetically modified organisms, the authority organises a public consultation lasting 30 days (in accordance with the Royal Decree of 21 February 2005). This gives you the opportunity, as a citizen, to share your opinion on the clinical trial application for the genetically modified drug PF-06939926 for the treatment of Duchenne muscular dystrophy. More information.